AG14361
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 401020

CAS#: 328543-09-5

Description: AG14361 is a PARP-1 inhibitor with Ki < 5 nmol/L. AG14361 is at least 1000-fold more potent than the benzamides. The IC50 for AG14361 is 29 nM in permeabilized SW620 cells and 14 nM in intact SW620 cells.

Chemical Structure

img
AG14361
CAS# 328543-09-5
Instruction

Theoretical Analysis

MedKoo Cat#: 401020
Name: AG14361
CAS#: 328543-09-5
Chemical Formula: C19H20N4O
Exact Mass: 320.16
Molecular Weight: 320.388
Elemental Analysis: C, 71.23; H, 6.29; N, 17.49; O, 4.99

Price and Availability

Size Price Availability Quantity
1mg USD 215
5mg USD 450
10mg USD 745
25mg USD 1645
Bulk inquiry

Synonym: AG14361; AG-14361; AG 14361.

IUPAC/Chemical Name: 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one.

InChi Key: SEKJSSBJKFLZIT-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)

SMILES Code: O=C1C2=C3C(N=C(C4=CC=C(CN(C)C)C=C4)N3CCN1)=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 320.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gu W, Ge R, Zhu F, Li D, Liang R, Ge J, Wang Y, Li B, Qiu J. PARP-1 inhibitor-AG14361 suppresses acute allograft rejection via stabilizing CD4+FoxP3+ regulatory T cells. Pathol Res Pract. 2020 Aug;216(8):153021. doi: 10.1016/j.prp.2020.153021. Epub 2020 May 21. PMID: 32703489.


2: Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14;434(7035):913-7. doi: 10.1038/nature03443. Erratum in: Nature. 2007 May 17;447(7142):346. PMID: 15829966.


3: Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res. 2004 Feb 1;10(3):881-9. doi: 10.1158/1078-0432.ccr-1144-3. PMID: 14871963.


4: Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004 Jan 7;96(1):56-67. doi: 10.1093/jnci/djh005. PMID: 14709739.


5: Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res. 2005 Dec 1;11(23):8449-57. doi: 10.1158/1078-0432.CCR-05-1224. PMID: 16322308.


6: Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene. 2009 Feb 12;28(6):832-42. doi: 10.1038/onc.2008.439. Epub 2008 Dec 8. Erratum in: Oncogene. 2023 Feb;42(7):546-547. PMID: 19060926; PMCID: PMC2642763.


7: Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Cancer Res. 2014 Jun 24;16(3):R67. doi: 10.1186/bcr3682. PMID: 24962108; PMCID: PMC4229979.


8: Leak RK, Zhang L, Luo Y, Li P, Zhao H, Liu X, Ling F, Jia J, Chen J, Ji X. Peroxiredoxin 2 battles poly(ADP-ribose) polymerase 1- and p53-dependent prodeath pathways after ischemic injury. Stroke. 2013 Apr;44(4):1124-34. doi: 10.1161/STROKEAHA.111.680157. Epub 2013 Feb 21. PMID: 23429506; PMCID: PMC3891055.


9: Kyle S, Thomas HD, Mitchell J, Curtin NJ. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297. PMID: 18820000.


10: Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007 Mar;6(3):945-56. doi: 10.1158/1535-7163.MCT-06-0552. PMID: 17363489.


11: Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009 Oct 1;15(19):6106-12. doi: 10.1158/1078-0432.CCR-09-0398. Epub 2009 Sep 29. PMID: 19789326; PMCID: PMC2756456.


12: Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009 Aug 15;69(16):6381-6. doi: 10.1158/0008-5472.CAN-09-1178. Epub 2009 Aug 4. PMID: 19654294; PMCID: PMC2754824.


13: De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci. 2006;2(4):179-85. doi: 10.7150/ijbs.2.179. Epub 2006 Jun 10. PMID: 16810332; PMCID: PMC1483123.


14: Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003 Sep 15;63(18):6008-15. PMID: 14522929.


15: Bryant HE, Helleday T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans. 2004 Dec;32(Pt 6):959-61. doi: 10.1042/BST0320959. PMID: 15506935.


16: Yuan P, Song F, Zhu P, Fan K, Liao Q, Huang L, Liu Z. Poly (ADP-ribose) polymerase 1-mediated defective mitophagy contributes to painful diabetic neuropathy in the db/db model. J Neurochem. 2022 Aug;162(3):276-289. doi: 10.1111/jnc.15606. Epub 2022 Mar 18. PMID: 35263449.


17: Smith AJ, Ball SS, Bowater RP, Wormstone IM. PARP-1 inhibition influences the oxidative stress response of the human lens. Redox Biol. 2016 Aug;8:354-62. doi: 10.1016/j.redox.2016.03.003. Epub 2016 Mar 7. PMID: 26990173; PMCID: PMC4799059.


18: Xiang J, Zhou L, He Y, Wu S. LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells. Aging (Albany NY). 2021 Dec 16;13(24):25920-25930. doi: 10.18632/aging.203780. Epub 2021 Dec 16. PMID: 34919531; PMCID: PMC8751605.


19: Li Q, Li ZM, Sun SY, Wang LP, Wang PX, Guo Z, Yang HW, Ye JT, Lu J, Liu PQ. PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy. Acta Pharmacol Sin. 2019 May;40(5):589-598. doi: 10.1038/s41401-018-0044-4. Epub 2018 Jul 20. PMID: 30030529; PMCID: PMC6786360.


20: Shi F, Wu L, Cui D, Sun M, Shen Y, Zhou Z, Deng Z, Han B, Xia S, Zhu Z, Sun F. LncFALEC recruits ART5/PARP1 and promotes castration-resistant prostate cancer through enhancing PARP1-meditated self PARylation. Cell Oncol (Dordr). 2023 Jun;46(3):761-776. doi: 10.1007/s13402-023-00783-z. Epub 2023 Mar 13. PMID: 36913068.